JP Morgan Chase
TCON

JP Morgan Chase’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

JP Morgan Chase’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$4 – 7971
2023
Q3 		$4 Buy
+1
New +$5 ﹤0.01% 7386
2021
Q4 		– Sell
-11
Closed -$1K – 7049
2021
Q3 		$1K Sell
11
-438
-98% -$37.1K ﹤0.01% 6416
2021
Q2 		$58K Buy
449
+353
+368% +$48.8K ﹤0.01% 5694
2021
Q1 		$16K Buy
+96
New +$18.5K ﹤0.01% 5742
2020
Q2 		– Sell
-1,704
Closed -$57K – 5776
2020
Q1 		$57K Buy
+1,704
New +$99K ﹤0.01% 4690
2018
Q4 		– Sell
-518
Closed -$212K – 5989
2018
Q3 		$212K Sell
518
-42
-8% -$19.4K ﹤0.01% 4673
2018
Q2 		$302K Buy
560
+360
+180% +$191K ﹤0.01% 4393
2018
Q1 		$92K Buy
200
+150
+300% +$81.8K ﹤0.01% 4616
2017
Q4 		$34K Buy
50
+36
+257% +$21.7K ﹤0.01% 5021
2017
Q3 		$9K Buy
+14
New +$7.29K ﹤0.01% 4738

Other funds holding TCON

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

JP Morgan Chase's TCON Position: Q4 2023 in Review

JP Morgan Chase sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2023, closing a stake of 1 share — an estimated $4 sold.

JP Morgan Chase first reported a position in TCON in Q3 2017 and held it in 10 quarters. The position peaked at $302K in Q2 2018. 24 funds tracked by Wall St. Rank hold TCON as of Q4 2023.

  • JP Morgan Chase reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1 TRACON Pharmaceuticals, Inc. Common Stock share in Q4 2023, an estimated $4.
  • JP Morgan Chase first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
  • JP Morgan Chase's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $302K in Q2 2018.
  • 24 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.